Blood Tests Offer Promise for Colorectal Cancer Detection, Yet Follow-Up Lags

Understanding the Challenges of Blood-Based Colorectal Cancer Screening

A recent study conducted by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has shed light on the effectiveness and limitations of blood-based colorectal cancer screening. While these tests offer a more convenient alternative for patients, the study found that only 49% of individuals completed a follow-up colonoscopy within six months of receiving an abnormal result. Over the course of two years, just 56% of participants followed through with the necessary procedure.

This data highlights a critical issue in the healthcare system: the importance of follow-up care after an initial screening. Colonoscopies are essential to confirm whether cancer or pre-cancerous conditions are present. Without this step, the benefits of early detection cannot be fully realized. The follow-up rates observed in this study are similar to those seen with traditional stool-based screening methods but still fall short of what is needed to ensure timely diagnosis and treatment.

Disparities in Follow-Up Rates

The study also uncovered significant disparities in follow-up rates among different patient groups. Individuals with Medicare Advantage were less likely to complete a colonoscopy compared to those with private insurance. This suggests that access to healthcare and the type of insurance coverage can play a major role in whether patients receive the necessary follow-up care.

Additionally, the research found that patients with fewer health conditions were more likely to complete their follow-up colonoscopies. This could indicate that individuals with complex medical needs may face additional barriers to accessing care, such as difficulty scheduling appointments or navigating the healthcare system.

Interestingly, the study did not find race or ethnicity to be significant predictors of follow-up completion. This contrasts with previous findings in studies involving stool-based screening, suggesting that blood-based tests may have a more equitable impact across different demographic groups.

The Role of Blood-Based Screening in Colorectal Cancer Detection

Colorectal cancer remains one of the leading causes of cancer-related deaths in the United States. Early detection through regular screening can significantly improve outcomes, yet many people do not undergo the recommended tests. Barriers such as fear, limited access to healthcare, and the complexity of preparing for traditional screenings like colonoscopies or stool-based tests often prevent individuals from getting screened.

Blood-based screening tests, such as Shield (developed by Guardant Health), provide a noninvasive and more convenient option for patients who may not be able to tolerate other forms of testing. These tests detect genetic markers in the blood that may indicate the presence of cancer or pre-cancerous conditions. However, the success of these tests depends on whether patients follow up with a colonoscopy when results are abnormal.

Study Methodology and Findings

The research team conducted a retrospective analysis using medical claims data from over 6,000 individuals aged 45 and older who received a blood-based colorectal cancer screening test between 2022 and 2024. The study focused on the 452 individuals who received an abnormal result and tracked how many completed a follow-up colonoscopy within six months.

Published in the journal Gastroenterology, the study provides valuable real-world insights into the challenges of ensuring that patients follow through with critical next steps after an abnormal screening result. Timely follow-up is essential for detecting and treating colorectal cancer at an early stage, which can significantly improve survival rates.

Key Researchers and Contributions

The study was led by Dr. Timothy Zaki, a senior gastroenterology fellow at UCLA Health, and Dr. Folasade May, associate professor of medicine at the David Geffen School of Medicine at UCLA. Other contributors included Nicole Zhang, Dr. Shaun Forbes, Victoria Raymond, and Dr. Amar Das from Guardant Health.

Dr. May emphasized the importance of follow-up care in maximizing the benefits of blood-based screening. “Blood-based colorectal cancer screening is promising, but it only works if individuals complete the follow-up colonoscopy,” she said. “More efforts are needed to help patients follow through to actually diagnose and treat the disease.”

Future Implications

As blood-based screening becomes more widely adopted, understanding and addressing the factors that influence follow-up rates will be crucial. Improving access to care, reducing barriers for high-risk populations, and implementing better patient education and support systems will be key steps in ensuring that these innovative tests translate into meaningful health outcomes.